| Document |
Document Title |
|
WO/2001/029156A2 |
2,5-dimercapto-1,3,4-thiadiazole dimer-poly(ether)glycol reaction products and adducts useful as extreme pressure additives. Lubricating compositions (e.g., greases) containing reaction products and adducts exhibit improved Timken Load p...
|
|
WO/2001/021623A1 |
The present invention includes novel (7R)-7-acylamino-3-heteroarylthio-3-cephem-4-carboxylic acids or their pharmacologically acceptable salts and prodrugs thereof, which exhibit antibiotic activity against a wide spectrum of organisms i...
|
|
WO/2001/021604A1 |
The invention relates to substituted piperazine derivatives of general formula (I), in which: n represents the number 1, 2, 3, 4, or 5; m represents the number 2 or 3; X represents a carbon-carbon bond, an oxygen atom, a methylene group,...
|
|
WO/2001/019780A2 |
The invention relates to compounds of formula (I) as well as the salts and stereoisomers thereof used in the production of medicaments for the treatment of cardiovascular diseases.
|
|
WO/2001/017982A1 |
The present invention includes benzophenone compounds (I) which are useful in the treatment of HIV infections.
|
|
WO/2001/017968A1 |
Compounds represented by general formula (I), tautomers thereof, prodrugs of both, pharmaceutically acceptable salts of them, or solvates thereof exhibit an integrase-inhibiting activity. In said formula, X is hydroxyl or the like; Y is ...
|
|
WO/2001/016121A1 |
In accordance with the present invention, there are provided novel class of heterocyclic compounds and methods of use thereof. Compounds of the invention contain a substituted, unsaturated five, six or seven membered heterocyclic ring th...
|
|
WO/2001/014339A2 |
Heterocyclic aromatic amides (HAA) according to Formula (I) wherein X¿1?-X¿4?, M, Z, and A are herein defined. The invention also encompasses hydrates, salts and complexes thereof. These compounds are useful as antifungal agents.
|
|
WO/2001/014310A1 |
Pleuromultilin $g(b)-ketoesters of Formula (IA) or (IB), in which R?1¿ is a nitrogen containing heterocycle, an optionally substituted aryl or optionally substituted heteroaryl group, or CH¿2?R?5¿; R?2¿ is vinyl or ethyl; R?3¿ is H,...
|
|
WO/2001/009109A1 |
The invention relates to novel 5-chlorodifluoromethyl-1,3,4-thiadiazol-2-yl-oxyacetanilides
of general formula (I) wherein: n represents 0, 1, 2 or 3,R represents straight-chained or branched alkyl with - 4 carbon atoms, and X stands fo...
|
|
WO/2001/005769A2 |
Heterocyclic aromatic amides having a hydroxy group adjacent to the amide functionality of Formula (I) wherein (a) represents a 5- or 6- membered heterocyclic aromatic ring in which (i) each of X¿1?-X¿4? is O, S, NR', N, CR' or a bond;...
|
|
WO/2001/005756A1 |
Compounds which are 3-arylsulfonyl-2-methyl propanoic acid derivatives of formula (I): wherein X is HO-NH- or HO-, R¿1? is selected from phenyl, 4-chlorophenyl, 4-fluorophenyl, 4-cyanophenyl, benzamido (i.e., -NH-CO-Ph) and benzamido su...
|
|
WO/2001/005777A1 |
The invention relates to compounds of formula (I), wherein Xn represents a hydrogen or defined substituents, R represents s-butyl, t-butyl, 1-ethyl-propyl, 2-propinyl, 1-methyl-2-propinyl, 1-ethyl-2-propinyl, 2-butinyl, 1-methyl-2-butiny...
|
|
WO/2001/005390A2 |
The invention features a method for treating chronic pain using a compound of formula (I) shown in claim 1 of the application.
|
|
WO/2001/005774A1 |
Heteroaromatic ring compounds and pharmaceutically acceptable salts thereof, including the compound of formula (I) and exhibiting excellent physical properties and potent ameliorative effects against both immune disorders and chronic inf...
|
|
WO/2001/005398A1 |
N-Aryl-2-sulfonamidobenzamides, useful for treatment of chronic renal failure and uremic bone disease, are disclosed.
|
|
WO/2001/002354A1 |
Heterocyclic amine derivatives represented by general formula (I) wherein R?1¿, R?2¿ and R?3¿ represent each H, optionally halogenated C¿3-6? cycloalkyl, etc.; Q represents an optionally substituted heterocycle containing O, S or N; ...
|
|
WO/2001/000600A1 |
The invention relates to N-substituted perhydro-2, 3-diazine of formula (I), wherein the variables Z, R, m and R?A¿ correspond to the definitions given in claim 1. The invention also relates to a method for the production of N-substitut...
|
|
WO/2001/000575A1 |
Heterocyclic dicarboxylic acid diamide derivatives represented by general formula (I): wherein R?1¿, R?2¿ and R?3¿ represent each H, optionally halogenated C¿3-6? cycloalkyl, etc.; Het represents a 5- or 6-membered heterocycle; X and...
|
|
WO/2001/000602A1 |
The invention relates to substituted ureas of general formula (Ia) and (Ib), wherein variables X, Z, m, R and R?A¿ have the meaning cited in claim 1 and Q represents one of radicals Q1 to Q6: (Q-1), (Q-2), (Q-3), (Q-4), (Q-5), (Q-6), wh...
|
|
WO/2000/078145A1 |
Macrophage scavenger receptor antagonists are provided. Methods of treating cardiovascular disease comprising administration of the present compounds are also provided. The present compounds inhibit lipid accumulation within macrophage-d...
|
|
WO/2000/073289A1 |
The invention relates to novel aryl-substituted S(O)¿m? cycles of formula (I), in which F?1¿, F?2¿, G, V, W, X, Y, Z and m have the meanings defined in the description. The invention further relates to methods for producing said cycle...
|
|
WO/2000/072840A1 |
This invention relates to the novel use of phenyl ureas in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8).
|
|
WO/2000/071118A1 |
The invention concerns novel phospholipase A¿2? specific inhibiting compounds of general formula (I). Said novel compounds are capable of acting on PLA¿2? and are advantageously PLA¿2?snp-specific inhibiting compounds completely inact...
|
|
WO/2000/068210A1 |
The invention relates to cyclohexenone derivatives of benzo-condensed, unsaturated 5-ring nitrogen heterocycles of general formula (I) wherein X represents N or a group C-R?3¿, Y represents O, S, SO, SO¿2? or NR?4¿ or X-Y represent S=...
|
|
WO/2000/067751A1 |
Compounds represented by formula (I): or a pharmaceutically acceptable salt or hydrate thereof, are disclosed. Pharmaceutical compositions and methods of treatment are also included.
|
|
WO/2000/068215A1 |
The invention encompasses compounds of Formula (I) as well as a method of treating COX-2 mediated diseases comprising administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound of ...
|
|
WO/2000/068204A1 |
The invention relates to novel substituted benzoyl ketones of formula (I), wherein n represents 0, 1, 2 or 3; A represents a simple bond or alkanediyl (alkylene); R?1¿ represents hydrogen or optionally substituted alkyl or cycloalkyl; R...
|
|
WO/2000/068216A1 |
The invention relates to compounds of general formula (I, II and III) and to a method for the production thereof, whereby compounds (III) are initially obtained in a first step and compounds (I and II) are obtained in a second step. Said...
|
|
WO/2000/066613A1 |
The present invention relates to compounds of formula (I) or formula (II) or pharmaceutically acceptable salts thereof useful for the prophylaxis and treatment of degenerative bone disorders, wherein A is (a), B is (b) and X, Y, E, V, Q,...
|
|
WO/2000/064881A1 |
The invention relates to novel O-aryl dithiazole dioxides, to two methods for producing the same and to the use thereof as pesticides for protecting plants and materials.
|
|
WO/2000/063195A1 |
The current invention discloses novel heterocyclic amino carbonyl derivatives useful as nitric oxide synthase inhibitors
|
|
WO/2000/061583A1 |
Novel heterocyclic compounds having a six membered ring structure fused to a five membered ring structure are found to be useful for the treatment and prevention of symptoms or manifestations associated with disorders affected by Interle...
|
|
WO/2000/060027A2 |
Compounds are provided of formula (I) wherein RJ is C¿n?H¿2n+1?CH=CHC¿m?H¿2m?Z¿1?; n may be 1-5; m may be 0-5; q may be 0, 1 or 2; A¿1?, A¿2?, A¿3?, R, Z, and J are as defined in the description. In particular it describes compou...
|
|
WO/2000/058293A2 |
The present invention relates to compounds of formula (I) wherein R?1¿, R?2¿, R?3¿ and R?4¿ are as defined in claim 1 and pharmaceutically acceptable salts thereof. The compounds are glucokinase activators which increase insulin secr...
|
|
WO/2000/058306A1 |
The invention relates to novel substituted benzoylpyrazoles of the general formula (I), in which Z is a possibly substituted 4 to 12-membered, saturated or unsaturated, monocyclic or bicyclic heterocyclic grouping which contains between ...
|
|
WO/2000/057878A1 |
A pharmaceutical composition that inhibits or slows the growth of viruses in animals, particularly in mammals, is disclosed. This same composition can be used to treat viral infections, particularly hepatitis C, herpes simplex, Kaposi's ...
|
|
WO/2000/057869A2 |
A pharmaceutical composition that inhibits or slows the infection or reinfection of animals, particularly mammals, by HIV or other retroviruses is disclosed. The composition comprises from about 10 mg to about 6000 mg of a (5-aryl- 1,2,4...
|
|
WO/2000/055126A2 |
The present invention relates to novel $i(N)-cyanomethyl amides which are cysteine protease inhibitors, the pharmaceutically acceptable salts and $i(N)-oxides thereof, their uses as therapeutic agents and the methods of their making.
|
|
WO/2000/055125A2 |
The present invention relates to novel N-cyanomethyl amides which are cysteine protease inhibitors, the pharmaceutically acceptable salts and N-oxides thereof, their uses as therapeutic agents and the methods of their making.
|
|
WO/2000/054759A2 |
The invention provides compounds, compositions and methods for modulating the effects of LXR in a cell. The compounds and compositions are useful both as diagnostic indicators of LXR function and as pharmacologically active agents. The c...
|
|
WO/2000/051975A1 |
Disclosed are compounds which are inhibitors of metalloproteases and which are effective in treating conditions characterized by excess activity of these enzymes. In particular, the compounds have a structure according to Formula (I) whe...
|
|
WO/2000/051999A1 |
The present invention provides compounds of general formula (1) wherein: two atoms of X, Y, or Z are nitrogen and the third atom is sulfur or oxygen; R is H, halogen, OH, SH, C¿1?-C¿6? alkyl, C¿1?-C¿6? alkoxy, C¿1?-C¿6? thioalkyl, ...
|
|
WO/2000/051993A2 |
Disclosed are compounds which are inhibitors of metalloproteases and which are effective in treating conditions characterized by excess activity of these enzymes. In particular, the compounds have a structure according to formula (I): wh...
|
|
WO/2000/050390A1 |
The present invention relates to a novel class of organic molecules capable of inhibiting C-proteinase, and to their use to regulate, modulate and/or inhibit abnormal collagen formation as a therapeutic approach towards the treatment of ...
|
|
WO/2000/047567A1 |
Heterodiazinone derivatives represented by general formula (1 ), pharmacologically acceptable salts of the same, or hydrates of both, exhibiting 2-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonism wherein A is...
|
|
WO/2000/046184A1 |
The invention provides fungicidal compounds of formula (I) and salts thereof wherein: R?1¿ is alkyl, alkenyl, alkynyl, carbocyclyl or heterocyclyl, each of which may be substituted, or hydrogen; R?2¿ and R?3¿, which may be the same or...
|
|
WO/2000/043369A1 |
Disclosed are compounds (Ia or Ib) which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases...
|
|
WO/2000/043372A1 |
Disclosed are compounds such as Ia and Ib which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory d...
|
|
WO/2000/041505A2 |
The invention features a compound having the formula (I) below. The invention also relates to a pharmaceutical composition including (a) a compound of formula (I) and (b) a pharmaceutically-acceptable carrier. The invention further relat...
|
